Hyperkalemia in heart failure: Foe or friend?
Key result
Novel potassium-binding drugs are effective in lowering potassium levels and are generally well tolerated, potentially allowing target doses of RAAS inhibitors to be achieved in heart failure.
Why the study?
Evaluating hyperkalemia's prevalence and significance in heart failure is essential for balancing life-saving potassium-sparing therapy against hyperkalemia risks.
Population
Patients with heart failure
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Hyperkalemia signals both arrhythmic risk and HF severity; leaves open optimal monitoring and RAASi titration strategies.
Structured PICO
P
Population
Patients with heart failure (HF)
I
Intervention
Novel potassium-binding drugs (patiromer and sodium zirconium cyclosilicate)
Novel potassium binders like patiromer and sodium zirconium cyclosilicate offer a well-tolerated strategy to manage hyperkalemia and enable guideline-directed RAASi dosing in heart failure.
Cite This Study
Rakisheva et al. (2020) conducted a review in Heart failure with hyperkalemia. Potassium-binding agents (patiromer, sodium zirconium cyclosilicate) was evaluated. Novel potassium-binding drugs are effective in lowering potassium levels and are generally well tolerated, potentially allowing target doses of RAAS inhibitors to be achieved in heart failure.